联合治疗肌醇加 D-手性肌醇，而不是 D-手性肌醇，能够改善试管婴儿结局：一项随机对照试验的结果。
The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
机构信息
Department of Psychology, Section of Neuroscience, University of Rome "Sapienza", Via dei Marsi 78, 00185, Rome, Italy.
出版信息
Arch Gynecol Obstet. 2013 Dec;288(6):1405-11. doi: 10.1007/s00404-013-2855-3. Epub 2013 May 25.
PURPOSE
The present study aims to investigate the effects of the combined therapy myo-inositol (MI) plus D-chiro-inositol (DCI) or D-chiro-inositol treatment in oocyte quality.
METHODS
Polycystic ovary syndrome (PCOS) women undergoing IVF-ET were treated with myo-inositol combined with D-chiro-inositol in the physiological ratio (1.1 g myo-inositol plus 27.6 mg of D-chiro-inositol; INOFOLIC combi Lo.Li.pharma) or D-chiro-inositol alone (500 mg; Interquim, s.a., Barcelona, Spain) to evaluate the umber of morphological mature oocytes, total International Units (IU) of recombinant FSH administered and the number of grade 1 embryos.
RESULTS
The data clearly showed that only the combined therapy was able to improve oocyte and embryo quality, as well as pregnancy rates, in PCOS women undergoing IVF-ET.
CONCLUSION
The present paper further supports the hypothesis that MI plays a crucial role in the ovary in PCOS women. In particular, due to the physiological role played by MI and DCI, the combined therapy should represent a better choice.
目的
本研究旨在探讨肌醇（MI）与 D-手性肌醇（DCI）联合治疗或 D-手性肌醇治疗对卵母细胞质量的影响。
方法
接受体外受精-胚胎移植（IVF-ET）的多囊卵巢综合征（PCOS）妇女接受肌醇与 D-手性肌醇按生理比例（1.1 g 肌醇加 27.6 mg D-手性肌醇；INOFOLIC combi Lo.Li.pharma）或单独 D-手性肌醇（500 mg；Interquim，s.a.，巴塞罗那，西班牙）联合治疗，以评估形态成熟卵母细胞的数量、重组促卵泡激素的总国际单位（IU）用量和 1 级胚胎的数量。
结果
数据清楚地表明，只有联合治疗才能改善 PCOS 妇女接受 IVF-ET 的卵母细胞和胚胎质量以及妊娠率。
结论
本研究进一步支持了 MI 在 PCOS 妇女卵巢中发挥关键作用的假说。特别是由于 MI 和 DCI 发挥的生理作用，联合治疗应该是更好的选择。
Zotero 插件